Utilización de pentoxifilina en fase aguda de enfermedad de La Peyronie / Use of Pentoxifylline in the acute phase of Peyronie's disease

INTRODUCCIÓN: existe una gran variedad de tratamientos orales para la Enfermedad de La Peyronie (EP), pero ninguno demostró ser efectivo. En los últimos años se ha propuesto a la Pentoxifilina (PTX) como un potencial agente para su tratamiento. OBJETIVO: evaluar la evolución clínica de los pacientes que recibieron PTX al menos 3 meses durante la fase aguda de la EP. MATERIALES Y MÉTODOS: estudio de cohorte retrospectivo y observacional. Los datos se obtuvieron de las historias clínicas de pacientes con diagnóstico de EP entre enero y octubre de 2017. Para la evaluación objetiva, se utilizaron autofotografías y técnica de Kelami. RESULTADOS: 93 hombres cumplieron con los criterios de inclusión. El tiempo medio de tratamiento con PTX fue de 7,9 meses, y el de seguimiento, 10,8 meses. El 59,1% de los pacientes no tuvo modificaciones en su curvatura, el 9,7% mejoró, mientras que el 31,2% empeoró. De 49 pacientes que penetraban sin dificultad, 34 (69,4%) no tuvieron cambios, 12 (24,5%) pasaron a tener dificultad y 3 (6,1%) se convirtieron en no penetradores (p 0,0001). De los 41 pacientes que tenían dificultad en la penetración, 13 (31,7%) pudieron penetrar sin dificultad, 7 (17,1%) pasaron a no poder hacerlo, mientras que el resto (21 pacientes) se mantuvo sin cambios (p 0,0001). La correlación entre la curvatura inicial y la curvatura luego del tratamiento medido en todos los pacientes fue significativa (p 0,028). CONCLUSIÓN: la PTX podría tener un efecto positivo en estabilizar la enfermedad, y los hombres con EP en fase aguda podrían beneficiarse con el tratamiento.

INTRODUCTION: There is a wide variety of oral treatments for Peyronie's Disease (PD) but none proved to be effective. In recent years, Pentoxifylline (PTX) has been proposed as a potential agent for the treatment. Objective: To evaluate the clinical evolution of patients who received PTX at least 3 months during the acute phase of PD. MATERIALS AND METHODS: Retrospective and observational cohort study. The data were obtained from the clinical records of patients diagnosed with PE between January 2007 and October 2017. For their objective evaluation, autographs and the Kelami technique were used. RESULTS: 93 men met the inclusion criteria. The mean time of treatment with PTX was 7.9 months and the follow-up time was 10.8 months. 59.1% of patients had no changes in their curvature, 9.7% improved, while 31.2% worsened. Of 49 patients who entered without difficulty in penetrating, 34 (69.4%) had no changes, 12 (24.4%) had difficulty and 3 (6.1%) became non-penetrators (p 0.0001). Of the 41 patients who had difficulty in penetrating, 13 (31.7%) could penetrate without difficulty, 7 (17.1%) were unable to do so, while the rest (21 patients) remained unchanged (p. 0.0001). The correlation between initial curvature and curvature after treatment measured in all patients was significant (p 0.028). CONCLUSION: PTX could have a positive effect in stabilizing the disease and men with acute phase PE could benefit with treatment.

Avaliação da pentoxifilina e do sulfato ferroso no tratamento da úlcera varicosa dos membros inferiores / Evaluation of pentoxifylline and ferrous sulfate for treatment of lower limb venous ulcers

Resumo Contexto A úlcera varicosa (UV) é o estágio mais avançado da doença venosa crônica (DVC) dos membros inferiores (MMII), frequentemente associada a episódios de hemorragia que podem provocar anemia crônica (AC) e retardar a sua cicatrização. Não há, na literatura, trabalhos que avaliem a prevalência da AC nos portadores de UV dos MMII, e poucos trabalhos analisam o uso da pentoxifilina no tratamento das UV dos MMII. Objetivos Avaliar a prevalência da AC nos pacientes portadores de UV de MMII e a resposta terapêutica ao sulfato ferroso (SF) e a associação da pentoxifilina com SF no tratamento adjuvante das UV dos MMII. Métodos Foram avaliados 67 pacientes portadores de UV de MMII atendidos no ambulatório de Cirurgia Vascular do Hospital das Clínicas, Recife, PE. Após as avaliações clínica e laboratorial iniciais, os pacientes diagnosticados com AC foram randomizados em dois grupos: o grupo controle, que recebeu SF (900 mg/dia via oral), e o grupo de estudo, tratado com SF (900 mg/dia via oral) e pentoxifilina (1.200 mg/dia). Todos foram reavaliados após 90 dias. Resultados Entre os pacientes avaliados, 27 (40%) apresentavam AC. Após o tratamento, foram observados aumento dos níveis de hemoglobina e de hematócrito e melhora das taxas da cinética do ferro, assim como a diminuição da profundidade e da área das UV em ambos os grupos, sem diferença estatística. Conclusões Foi encontrada alta prevalência de anemia na população estudada. A associação do SF com a pentoxifilina não se mostrou mais eficaz do que o emprego isolado do SF no tratamento adjuvante da UV dos MMII.

Abstract Background Venous ulcers (VU) are the most advanced stage of chronic venous disease (CVD) of the lower limbs. They are frequently associated with episodes of hemorrhage that can provoke chronic anemia (CA), delaying healing. There are no studies in the literature analyzing the prevalence of CA among patients with VU of the lower limbs and few studies have analyzed use of pentoxifylline to treat VU of the lower limbs. Objectives To evaluate the prevalence of CA in patients with lower limb VU and responses to treatment with ferrous sulfate (SF) compared with a combination of SF plus pentoxifylline as adjuvant treatment for VU of the lower limbs. Methods A total of 67 patients with lower limb VU were recruited from a Lymphedema and Angiodysplasia Clinic at the Hospital das Clínicas, Recife, PE, Brazil. After initial clinical and laboratory assessments, patients diagnosed with CA were randomized into one of two groups: a control group, given SF (900 mg/day oral route), or a study group, treated with SF (900 mg/day oral route) and pentoxifylline (1,200 mg/day). All were reassessed after 90 days. Results Twenty-seven patients (40%) had CA. After treatment, increases were observed in hemoglobin and hematocrit levels, iron kinetics had improved, and both depth and area of VU had reduced in both groups, without statistically significant differences. Conclusions A high prevalence of anemia was detected in the study population. The combination of SF and pentoxifylline was not more effective than SF alone for adjuvant treatment of VU of the lower limbs.

Vasculopatia livedoide tratada com rivaroxabana / Livedoid vasculopathy treated with rivaroxaban

A vasculopatia livedoide é uma doença rara caracterizada pela oclusão da microvasculatura da derme, originando lesões maculosas que, posteriormente, podem evoluir para úlceras e cicatrizes atróficas. Como um fenômeno vaso-oclusivo, o tratamento geralmente é realizado com antiplaquetários e fibrinolíticos. O presente relato descreve o caso de uma paciente refratária à terapia convencional, que obteve regressão da doença utilizando a rivaroxabana, um fármaco inibidor seletivo do fator Xa. (AU)

Livedoid vasculopathy is a rare disease characterized by occlusion of the dermis microvasculature, leading to spotted lesions that can later develop into ulcers and atrophic scars. As a vaso- occlusive phenomenon, treatment is usually performed with antiplatelet and fibrinolytic agents. The present report describes the case of a female patient refractory to conventional therapy who presented disease remission using rivaroxaban, a selective factor Xa inhibitor drug. (AU)

The expression of endothelial and inducible nitric oxide synthase and apoptosis in intestinal ischemia and reperfusion injury under the action of ischemic preconditioning and pentoxifylline

Abstract Purpose: To investigate the expression of nitric oxide synthase (NOS) and apoptosis associated with ischemic preconditioning (IPC) and pentoxifylline (PTX) in intestinal ischemia (I) and reperfusion (R) injury. Methods: Thirty male rats were assigned to 5 groups: (CG), no clamping of the superior mesenteric artery (90 minutes); (IR-SS) saline + ischemia (30 minutes) + reperfusion (60 minutes); (IR-PTX) PTX + ischemia (30 minutes) + reperfusion (60 minutes); (IPC-IR-SS) 5 minutes of ischemia + 5 minutes of reperfusion (IPC) + saline + I(30 minutes)+R(60 minutes); and (IPC-IR-PTX) IPC + PTX + I(30 minutes)+ R(60 minutes). Results: The application of IPC and PTX showed a significantly lower immunohistochemistry reaction for active caspase-3 (P<0.05) compared to IR+SS. The number of cells immunoreactive to BCL-2 was higher in the IR-PTX group (P>0.05). The NOS-2 expression (qRTPCR) in the IR-PTX group (P<0.05) was higher than the values for the IPC+IR-SS and IPC-IR-PTX groups. The NOS-3 expression was significantly upper in the IPC-IR-PTX group than in the CG (P<0.05), the IR-SS (P<0.05) and the IR-PTX (P<0.05) groups. Conclusions: The BCL-2 and active caspase-3 showed beneficial effects on PTX and IPC. The expression of NOS-2 and NOS-3 in the IPC and IPC-PTX groups showed no synergistic effect.

The role of ischemic preconditioning and pentoxifylline in intestinal ischemia/reperfusion injury of rats

Abstract Purpose: To investigate the role of ischemic preconditioning (IPC) and pentoxifylline (PTX) in intestinal mucosa ischemia/reperfusion injury (IR). Methods: Thirty rats were assigned to 5 groups (N=6): (CG): no clamping of the superior mesenteric artery (90 min.); (IR-SS): saline + ischemia (30 min.) + reperfusion (60 min.); (IR-PTX): PTX + ischemia (30min.) + reperfusion (60 min.); (IPC-IR-SS): 5 min. of ischemia + 5 minutes of reperfusion (IPC) + saline + ischemia (30 min.) + reperfusion (60 min.); (IPC-IR-PTX ): 5 min. of ischemia + 5 min. of reperfusion (IPC) + PTX + 30 min. of I + 60 minutes of R. Results: The IR-PTX, IPC-IR-SS and IPC-IR-PTX groups had significantly lower scores of mucosa damage than the IR-SS group. IR-PTX group showed higher scores than the IPC-IR-PTX group, in accordance with the hypothesis of a favorable effect of IPC alone or in association with PTX. Additionally, IPC-IR-SS had a higher damage score than the IPC-IR-PTX. The villi height and crypt depth were similar in all groups. The villi height in the IR-SS was significantly lower. Conclusion: Ischemic preconditioning or pentoxifylline alone protect the intestinal mucosa from ischemia/reperfusion injury. However, they do not have a synergistic effect when applied together.

Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats

ABSTRACT PURPOSE: To evaluate the effects of an intraperitoneal solution of methylene blue (MB), lidocaine and pentoxyphylline (PTX) on intestinal ischemic and reperfusion injury METHODS: Superior mesenteric artery was isolated and clamped in 36 adult male Sprague Dawley rats. After 60 minutes, clamp was removed and a group received intraperitoneally UNITO solution (PTX 25mg/kg + lidocaine 5mg/kg + MB 2mg/kg), while the other group was treated with warm 0.9% NaCl solution. Rats were euthanized 45 min after drug administration. Lung and bowel were collected for histological evaluation (using Park's score) and determination of myeloperoxidase (MPO) and malondialdehyde (MDA) levels. RESULTS: Control samples showed lymphoplasmocytic infiltrate and crypt necrosis of villi. MPO and MDA measurements shown no differences between treated and control groups. CONCLUSION: The combination of lidocaine, methylene blue and pentoxyphylline administered intraperitoneally at the studied dose, did not decreased histological lesion scores and biochemical markers levels in intestinal ischemia/reperfusion injury.

Effects of N-acetylcysteine and pentoxifylline on remote lung injury in a rat model of hind-limb ischemia/reperfusion injury / Efeitos da N-acetilcisteína e pentoxifilina na lesão pulmonar remota em um modelo de lesão de isquemia/reperfusão de membro posterior em ratos

Objective : To investigate the effects of N-acetylcysteine (NAC) and pentoxifylline in a model of remote organ injury after hind-limb ischemia/reperfusion (I/R) in rats, the lungs being the remote organ system. Methods : Thirty-five male Wistar rats were assigned to one of five conditions (n = 7/group), as follows: sham operation (control group); hind-limb ischemia, induced by clamping the left femoral artery, for 2 h, followed by 24 h of reperfusion (I/R group); and hind-limb ischemia, as above, followed by intraperitoneal injection (prior to reperfusion) of 150 mg/kg of NAC (I/R+NAC group), 40 mg/kg of pentoxifylline (I/R+PTX group), or both (I/R+NAC+PTX group). At the end of the trial, lung tissues were removed for histological analysis and assessment of oxidative stress. Results : In comparison with the rats in the other groups, those in the I/R group showed lower superoxide dismutase activity and glutathione levels, together with higher malondialdehyde levels and lung injury scores (p < 0.05 for all). Interstitial inflammatory cell infiltration of the lungs was also markedly greater in the I/R group than in the other groups. In addition, I/R group rats showed various signs of interstitial edema and hemorrhage. In the I/R+NAC, I/R+PTX, and I/R+NAC+PTX groups, superoxide dismutase activity, glutathione levels, malondialdehyde levels, and lung injury scores were preserved (p < 0.05 for all). The differences between the administration of NAC or pentoxifylline alone and the administration of the two together were not significant for any of those parameters (p > 0.05 for all). Conclusions : Our results suggest that NAC and pentoxifylline both protect lung tissue from the effects of skeletal muscle I/R. However, their combined use does not appear to increase the level of that protection.

Objetivo : Investigar os efeitos da N-acetilcisteína (NAC) e pentoxifilina em um modelo de lesão pulmonar remota após isquemia/reperfusão (I/R) de membro posterior em ratos. Métodos : Trinta e cinco ratos Wistar machos foram divididos em cinco grupos (n = 7/grupo), cada qual submetido ao seguinte: operação simulada (grupo controle); isquemia de membro posterior, induzida por pinçamento da artéria femoral esquerda por 2 h, seguida por de 24 h de reperfusão (grupo I/R); e isquemia de membro posterior, como descrito acima, seguida de injeção intraperitoneal (antes da reperfusão) de 150 mg/kg de NAC (grupo I/R+NAC), 40 mg/kg de pentoxifilina (grupo I/R+PTX) ou ambas (grupo I/R+NAC+PTX). Ao final do experimento, tecidos pulmonares foram removidos para análise histológica e avaliação do estresse oxidativo. Resultados : Comparados aos ratos dos outros grupos, os do grupo I/R apresentaram menor atividade de superóxido dismutase e menores níveis de glutationa, além de maiores níveis de malondialdeído e maiores escores de lesão pulmonar (p < 0,05 para todos). Infiltração celular inflamatória intersticial dos pulmões também foi bem maior no grupo I/R do que nos outros grupos. Além disso, os ratos do grupo I/R apresentaram vários sinais de edema intersticial e hemorragia. Nos grupos I/R+NAC, I/R+PTX e I/R+NAC+PTX, a atividade de superóxido dismutase, níveis de glutationa, níveis de malondialdeído e escores de lesão pulmonar foram preservados (p < 0,05 para todos). As diferenças entre a administração de NAC ou pentoxifilina isoladamente e a das duas combinadas não foi significativa para nenhum desses parâmetros (p > 0,05 para todos). Conclusões : Nossos resultados sugerem que tanto NAC quanto pentoxifilina protegem o tecido pulmonar dos efeitos de I/R de músculo esquelético. Entretanto, seu uso combinado não parece aumentar o nível dessa proteção.

Pentoxifilina no tratamento da leishmaniose tegumentar mucosa / Pentoxifylline in the treatment of mucosal tegumentary leishmaniasis

Contexto: No Brasil, a leishmaniose tegumentar é uma das doenças infecciosas que merece maior atenção, especialmente devido a sua alta magnitude e ao risco de ocorrência de deformidades permanentes nos indivíduos acometidos. Ela pode se apresentar nas seguintes formas clínicas: cutânea, disseminada, mucosa ou mucocutânea e difusa. No período de 2009 a 2013 foram registrados, em média, 21.395 casos/ano, distribuídos em todas as Unidades Federativas do Brasil. Algumas pesquisas têm demonstrado sucesso no emprego da pentoxifilina como coadjuvante no tratamento da leishmaniose mucosa, com desfecho de cura em menor tempo quando comparado ao tratamento convencional. Pergunta: Há evidências de que a pentoxifilina é eficaz e segura no tratamento de pacientes com leishmaniose mucosa? Evidências científicas: Após busca em bases de dados da literatura científica, foram encontradas 4 referências sobre o uso da pentoxifilina no tratamento da leishmaniose mucosa (LM): 3 revisões sistemáticas e 1 ensaio clínico randomizado. Uma das revisões se baseou em uma série de casos de 10 pacientes com LM refratária e as outras 2 revisões sistemáticas incluíram o mesmo ensaio clínico randomizado, já selecionado na busca, com 23 pacientes adultos com LM. Tanto a série de casos, quando o ensaio clínico foram realizados na Bahia e incluíram pacientes infectados por L. braziliensis. Em ambos os estudos, a terapia com pentoxifilina associada ao tratamento padrão com antimonial levou a uma taxa de cura maior e mais rápida das lesões do que a terapia com o antimonial isolado. Os membros da CONITEC presentes na reunião do plenário do dia 05/11/2015 - Deliberaram, por unanimidade, por recomendar a ampliação do uso da pentoxifilina 400mg em \r\nassociação ao antimonial para o tratamento da Leishmaniose Tegumentar Mucosa. A Portaria Nº 67, de 19 de novembro de 2015 - Torna pública a decisão de ampliar o uso da pentoxifilina 400 mg em associação ao\r\nantimonial para o tratamento da leishmaniose tegumentar mucosa no âmbito do Sistema Único de Saúde - SUS.

Partial Priapism Treated with Pentoxifylline

ABSTRACTMain findings:A 26-year-old man suffering from partial priapism was successfully treated with a regimen including pentoxifylline, a nonspecific phosphodiesterase inhibitor that is often used to conservatively treat Peyronie's disease.Case hypothesis:Partial priapism is an extremely rare urological condition that is characterized by thrombosis within the proximal segment of a single corpus cavernosum. There have only been 36 reported cases to date. Although several factors have been associated with this unusual disorder, such as trauma or bicycle riding, the etiology is still not completely understood. Treatment is usually conservative and consists of a non-steroidal anti-inflammatory and anti-thrombotic.Promising future implications:This case report supports the utilization of pentoxifylline in patients with partial priapism due to its anti-fibrogenic and anti-thrombotic properties.

Managing alcoholic liver disease

Alcoholic liver disease continues to be a significant cause of liver-related morbidity and mortality throughout the world. A number of diagnostic and prognostic models have been developed in the management of this condition, although specific roles for liver biopsy still remain particularly in the setting of alcoholic hepatitis. Despite a large number of recent treatment trials, the ideal pharmacotherapy approach remains undefined. Most essential is the supportive care and focus on abstinence and nutrition. Owing in part to a great deal of attention from governmental funding sources, a number of new treatment approaches are undergoing rigorous evaluation, hopefully providing future treatment options in this very severe condition.

Diagnostic and Therapeutic Strategies for Severe Alcoholic Hepatitis / 대한소화기학회지

Alcoholic hepatitis (AH) is defined as an acute hepatic manifestation resulting from heavy alcohol intake. Histologically, alcoholic steatohepatitis (ASH) is characterized by hepatocellular steatosis, inflammation, and fibrosis. Alcohol abstinence is the sine qua non of therapy for AH and, in the milder forms, is prerequisite to clinical recovery. Severe ASH may lead to multi-organ failure such as acute kidney injury and infection, which has a major impact on survival and thus should be closely monitored. Patients with severe ASH have a drastic short-term mortality of up to 40-50%. Specific therapies should be considered for patients with severe ASH at risk of early death. Corticosteroids are the standard of care for patients with severe ASH. When corticosteroids are contraindicated, pentoxifylline may be an alternative option. Steroid responsiveness should be evaluated on the basis of Lille score. Tactically, we should explore novel therapeutic targets to suppress inflammation based on cytokine profiles, promote hepatic regeneration, limit innate immune responses, and restore altered gut mucosal integrity in severe ASH.

Pentoxifylline associated to hypertonic saline solution attenuates inflammatory process and apoptosis after intestinal ischemia/reperfusion in rats

PURPOSE: To evaluate intestinal inflammatory and apoptotic processes after intestinal ischemia/reperfusion injury, modulated by pentoxifylline and hypertonic saline. METHODS: It was allocated into four groups (n=6), 24 male Wistar rats (200 to 250g) and submitted to intestinal ischemia for 40 min and reperfusion for 80 min: IR (did not receive any treatment); HS group (Hypertonic Saline, 4ml/kg-IV); PTX group (Pentoxifylline, 30mg/kg-IV); HS+PTX group (Hypertonic Saline and Pentoxifylline). All animals were heparinized (100U/kg). At the end of reperfusion, ileal fragments were removed and stained on hematoxylin-eosin and histochemical studies for COX-2, Bcl-2 and cleaved caspase-3. RESULTS: The values of sO2 were higher on treated groups at 40 minutes of reperfusion (p=0.0081) and 80 minutes of reperfusion (p=0.0072). Serum lactate values were lower on treated groups after 40 minutes of reperfusion (p=0.0003) and 80 minutes of reperfusion (p=0.0098). Morphologic tissue injuries showed higher grades on IR group versus other groups: HS (p=0.0006), PTX (p=0.0433) and HS+PTX (p=0.0040). The histochemical study showed lesser expression of COX-2 (p=0.0015) and Bcl-2 (p=0.0012) on HS+PTX group. A lower expression of cleaved caspase-3 was demonstrated in PTX (p=0.0090; PTXvsIR). CONCLUSION: The combined use of pentoxifylline and hypertonic saline offers best results on inflammatory and apoptotic inhibitory aspects after intestinal ischemia/reperfusion. .

Glucocorticoid influence on prognosis of idiopathic sudden sensorineural hearing loss / Influência dos corticosteroides no prognóstico auditivo da perda auditiva neurossensorial súbita idiopática

INTRODUCTION: Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is defined when a loss of at least 30 dB occurs in over 3 continuous frequencies, in up to 72 hours, of which etiology is not established, despite adequate investigation. Different types of treatment regimens have been proposed, but only glucocorticoids have shown some evidence of benefit in the literature. OBJECTIVE: To analyze whether the type of treatment or time of treatment with glucocorticoids have any influence on hearing recovery in ISSHL. METHODS: Observational retrospective cohort study. One hundred twenty-seven patients with ISSHL, treated at outpatient clinics between the years 2000 and 2010, were studied. We evaluated the prognostic correlation of the type of treatment and time to treatment with glucocorticoids and ISSHL. RESULTS: The absolute hearing gain and the relative hearing gain was as follows: 23.6 dB and 37.2%. Complete recovery was observed in 15.7% of patients, significant recovery in 27.6% and recovery in 57.5%. CONCLUSION: In this study, there was no difference between the use and nonuse of glucocorticoids in hearing improvement. However, when started within seven days after onset, the use of glucocorticoids was a factor of better prognosis. .

INTRODUÇÃO: A perda auditiva neurossensorial súbita idiopática (PANSSI) é definida pela queda dos limiares auditivos tonais de, pelo menos, 30 dB em três frequências contíguas em até 72 horas e apesar de uma investigação apropriada, a etiologia da lesão não é encontrada. Diversos tipos de tratamentos já foram idealizados para a PANSSI, no entanto, os corticosteroides são os que encontram as melhores evidências de efetividade na literatura. OBJETIVO: Avaliar se o tipo de tratamento e o tempo de demora em iniciar o tratamento com corticosteroides têm correlação com a melhora dos limiares auditivos na PANSSI. MÉTODOS: Estudo de coorte retrospectivo observacional. Foram avaliados 127 pacientes com PANSSI provenientes do ambulatório entre os anos de 2000 e 2010. Foi avaliada a correlação prognóstica do tipo de tratamento e tempo de demora para o início de tratamento e a PANSSI. RESULTADOS: As taxas de recuperação absoluta e relativa foram 23,6 dB e 37,2% respectivamente. Apresentaram melhora completa 15,7% dos pacientes, 27,6% apresentaram melhora significativa e 57,5% melhora. CONCLUSÃO: Neste estudo, não houve diferença entre o uso ou não de corticosteroide na melhora auditiva. Contudo, quando iniciado até sete dias, o uso de corticosteroide foi fator de melhor prognóstico. .

Pentoxifilina como tratamiento efectivo de la lipoidoproteinosis / Pentoxifylline as an effective treatment of lipoidoproteinosis

La lipoido proteinosis es una enfermedad rara, que ocurre por un defecto en el gen que codifica la proteína de la matriz extracelular 1 (ECM1). Estogenera un aumento del colágeno tipo IV, que resulta en depósitos de material hialino anómalo en la dermis y otros tejidos. Actualmente no hay terapias curativas y los múltiples tratamientos utilizados han tenido resultados variables y efectos adversos relevantes.La pentoxifilina es un fármaco que inhibe al factor de crecimiento transformante beta (TGF-beta) y así, regula la producción de colágeno por los fibroblastos. Se ha empleado con éxito en casos de fibrosis renal, hepática y pulmonar y luego de la radioterapia. Se presenta este caso que constituye la primera comunicación de lipoidoproteinosis tratada con pentoxifilina, en el que se evidenció una mejoría clínica, ecográfica y laringoscópica.

Lipoid proteinosisis a rare disease, causedby a defect in the gene encoding the extracellular matrix protein 1 (ECM1), that leads to an increased of collagen type IV, resulting in abnormal deposits of hyaline material in the dermis and other tissues. Currently, there are no curative therapies; several ones have been used with varied results and adverse effects. Pentoxifylline is a drug with inhibitory effect on TGF-beta, thus regulates collagen production by fibroblasts. It has been successfully used in renal, liver and lung transplant and after radiotherapy fibrosis. We present this case because it is the first report of lipoid proteinosis treated with pentoxifylline; with demonstrated clinical, sonographic and laryngoscopic improvement.

A comparative study of pentoxifylline effects in adult and aged rats submitted to lung dysfunction by thermal injury

PURPOSE: To investigate the protective effects of pentoxifylline against lung injury observed after dorsal scald in aged animals. METHODS: Adult (eight months old) and aged (20 months old) rats were subjected to thermal injury or sham procedure. The six hours post-trauma animals received pentoxifylline and after 24 hours were euthanatized and lung tissue samples collectedted. The bronchoalveolar lavage fluid was evaluated for total protein content and tumor necrosis factor-alpha cytokine. Malondialdehyde and myeloperoxidase activety in the lung homogenate were measured and a histological lung examination was undertaken. RESULTS: Burn injury induced oxidative stress in lung homogenate was higher in elderly-burned rats compared to adult-burned rats (p<0.001). Total protein and cytokine in bronchoalveolar lavage increased in the elderly-burned group when compared to the adult-burned group (p<0.001). All parameters decreased in bolth groups treated with pentoxifylline (p<0.05). CONCLUSIONS: The injury was augmented in elderly rats when compared to adult rats. Damage was reduced with the use of pentoxifylline, however further studies are needed to evaluate the dose-response of the drug.

Eficácia das terapias não convencionais (Pentoxifilina e Nicotinamida/Alopurinol) comparadas a metilprednisolona intravenosa no tratamento da oftalmopatia de Graves / Effectiveness of unconventional therapies ( Pentoxifylline and Nicotinamide / Allopurinol ) compared to intravenous methylprednisolone in the treatment of Graves' ophthalmopathy

A oftalmopatia de Graves (OG) se constitui em uma das manifestações clínicas mais marcantes da Doença de Graves. Mais freqüente em mulheres, pode atingir qualquer faixa etária e produzir alterações negativas na qualidade de vida dos pacientes acometidos. Trata-se de doença auto-imune cuja fisiopatologia centra-se em atividade inflamatória desencadeada por diversos antígenos presentes nos tecidos extra-ocular, com infiltrado linfocitário importante, adipogênese e produção de glicosaminoglicanos levando ao aspecto típico de inflamação e proptose. Os casos mais leves podem ser tratados com medidas locais, enquanto que casos mais graves, frequentemente, recebem terapia com glicocorticoides, particularmente pulsoterapia com metilprednisolona. O objetivo deste estudo foi comparar o uso de dois esquemas terapêuticos (associação de nicotinamida/alopurinol ou pentoxifilina por via oral) com a terapia padrão (corticóide em pulsoterapia). Foram recrutados pacientes portadores de OG classificados como moderada ou moderadamente grave e em atividade (definidos pelo NO SPECS e CAS) , distribuídos em três grupos de tratamento, a saber : G1- Pentoxifilina , G2- Nicotinamida/Alopurinol e G3- Metiprednisolona em pulsoterapia, distribuídos por conveniência. Para investigar a resposta ao tratamento clínico instituído, foram usados o CAS, a medida da proptose ocular por meio de exoftalmômetro, a dosagem de interleucinas séricas(TNF-α e IL-6), registros fotográficos dos olhos dos pacientes avaliados e a TC de órbitas...

Graves ’ophthalmopathy (GO) constitutes one of the most striking manifestations of Graves’ disease. More common in women, ocurr at any age group and produce negative changes in the quality of life of affected patients. It is an autoimmune disease whose physiopathology focuses on various inflammatory activity triggered by antigens present in extraocular tissues with significant lymphocyte infiltration, production of glycosaminoglycansadipogenesis leading to the typical appearance of inflammation and proptosis. The mild cases can be treated with local measures, while more serious cases often receive glucocorticoid therapy, particularly methylprednisolone pulse therapy. The aim of this study was to compare the use of two regimens (combination of nicotinamide / allopurinol or pentoxifylline orally) with standard therapy (intravenous steroid pulse therapy). We recruited patients with OG classified as moderate or moderately severe and active (defined by NO SPECS and CAS), divided into three treatment groups, namely: Pentoxifylline-G1, G2-Nicotinamide /Allopurinol-and G3 Metiprednisolona in pulse, distributed for convenience. To investigate the response to clinical treatment, the CAS were used to measure the ocular proptosis through exophtalmomether, the dosage of serum interleukins (TNF-α and IL-6), photographic records of the eyes of patients evaluated CT orbits...

Uso de la pentoxifilina en un niño con disfunción múltiple de órganos e isquemia aguda femoral: presentación de un caso / Use of pentoxifylline in a boy with multiple dysfunction of organs and acute femoral ischemia: a case presentation

La sepsis constituye aún un desafío para el pediatra. El éxito de su tratamiento requiere del reconocimiento precoz de la infección, de una terapia antimicrobiana apropiada y de un soporte respiratorio, quirúrgico y cardiovascular agresivo. Se presenta un lactante de dos meses de edad, blanco, masculino, con antecedentes de haber recibido la inmunización correspondiente según el esquema de vacunación; dos días después comienza con vómitos, hace crisis de cianosis, hipotonía, llanto débil y es llevado con urgencia al cuerpo de guardia de pediatría donde llega casi fallecido, se encontraba con severos trastornos hemodinámicos sin respuesta a estímulos dolorosos y mirada fija. Al ingreso se intenta realizar abordaje venoso profundo a través del eje femoral izquierdo, pero resultó fallido, le provocó secundariamente un espasmo arterial sin sangramiento activo por la puntura, temperatura y movilidad espontánea normales. Se realizó tratamiento con pentoxifilina intravenosa, se obtuvo un resultado exitoso en la pierna afectada y mejoría de otras funciones que se encontraban en fallo.

Periungual leishmaniasis / Leishmaniose periungueal

The vast majority of cases of cutaneous leishmaniasis are represented by limb injuries. A female patient, white, presented an ulcer with infiltrated borders located on the fourth finger of the left hand following occupational exposure in an area of native forest. Diagnosis of cutaneous leishmaniasis caused by Leishmania of the subgenus Viannia was confirmed. The patient failed to respond to treatment with antimony, but achieved clinical cure after this was associated with pentoxifylline. The case highlights the rarity of the periungual location of the leishmanial lesion and the difficulties encountered in therapy.

A grande maioria dos casos de leishmaniose tegumentar é representada por lesões nos membros. Paciente feminina, branca, diabética, apresentou úlcera com bordas infiltradas, localizada no quarto quirodáctilo esquerdo, após exposição ocupacional em área de mata nativa. Foi confirmado o diagnóstico de leishmaniose tegumentar por Leishmania do subgênero Viannia. Não respondeu ao tratamento com antimonial, mas obteve cura clínica após associação com a pentoxifilina. O caso destaca-se pela raridade da localização periungueal da lesão leishmaniótica e pela dificuldade terapêutica.

Pretreatment with pentoxifylline attenuates lung injury induced by intestinal ischemia/reperfusion in rats / Pré-tratamento com pentoxifilina atenua a lesão pulmonar induzida por isquemia/reperfusão intestinal em ratos

PURPOSE: To investigate the protective effect of pentoxifylline against the lung injury observed after intestinal ischemia (I) followed by a period of reperfusion (R). METHODS: Twenty-eight male Wistar rats were equally divided into 4 experimental groups and operated under ketamine-xylazine anesthesia. (1) Sham: falsely-operated animals; (2) SS+IR: intestinal ischemia was accomplished by clipping the superior mesenteric artery during 60 minutes, with an administration of a standard volume of saline solution (SS) 5 min before the end of the ischemia period; the clip was then releases or a 120-min period of reperfusion; (3) I+PTX+R: ischemia as above, PTX was administered (25 mg/kg) and the gut reperfused as above; (4) PTX+I+PTX+R: Five minutes before arterial occlusion PTX was administered; the superior mesenteric artery was then clipped for 60 minutes. After 55-min ischemia, an additional dosis of PTX was administered; the clip was removed for reperfusion as above. At the 60th min of reperfusion a third dosis of PTX was administered. RESULTS: PTX markedly attenuated lung injury as manifested by significant decreases (all P<0.001 as compared with the SS+IR group) of pulmonary wet/dry tissue weight ratio, total protein content, myeloperoxidase activity and tumor necrosis factor-alpha. Moreover, it was apparent that in the group PTX+I+PTX+R the improvements have been even more significant. CONCLUSION: PTX exerted a protective effect on the lung from the injuries caused by intestinal ischemia/reperfusion.

OBJETIVO: Avaliar os efeitos protetores da pentoxifilina (PTX) na lesão pulmonar observada após isquemia (I) seguida de reperfusão (R) intestinal. MÉTODOS: Vinte e oito ratos machos foram divididos aleatoriamente em quatro grupos experimentais e operados sobre anestesia quetamina-xilazina. (1) Sham: animais falsamente operados; (2) SS+IR: isquemia intestinal realizada pelo clampeamento da artéria mesentérica superior durante 60 minutos, com a administração de solução salina (SS) 5 minutos antes do período de isquemia, após a retirada do clamp houve a reperfusão por mais 120 minutos; (3) I+PTX+R: isquemia como mencionado anteriormente seguida da administração de PTX (25 mg/Kg) 5 minutos antes do final da isquemia (60 minutos) seguida de reperfusão por mais 120 minutos; (4) PTX+I+PTX+R: 5 minutos antes da isquemia foi administrado PTX, após 55 minutos de isquemia foi administrado outra dose de PTX e a reperfusão mantida por mais 120 minutos, sendo que aos 60 minutos da reperfusão outra dose de PTX foi administrada. RESULTADOS: A pentoxifilina reduziu os marcadores de lesão pulmonar (proteínas totais, malondialdeído, atividade da mieloperoxidase e fator de necrose tumoral) quando comparada com o grupo não tratado (P<0.001), contudo esta redução foi mais significante no grupo PTX+I+PTX+R. CONCLUSÃO: A pentoxifilina exerce efeito protetor no pulmão no trauma causado por isquemia/reperfusão intestinal.

Avanços no tratamento da leishmaniose tegumentar do novo mundo nos últimos dez anos: uma revisão sistemática da literatura / Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review

INTRODUÇÃO: O arsenal terapêutico contra a leishmaniose tegumentar é muito restrito. Os antimoniais pentavalentes permanecem como as drogas de escolha para seu tratamento há mais de 50 anos. Apesar da sua eficácia, necessita de injeções diárias, apresenta muitos efeitos colaterais e tempo de cura prolongado.

INTRODUCTION: The therapeutic arsenal against cutaneous leishmaniasis is very limited. Pentavalent antimonial compounds have been the drugs of choice for treatment of this disease for over 50 years. Despite their effectiveness, these drugs require daily injections, have many side effects and present prolonged healing time.